Order Article Reprints

Shoji T, Eto H, Sato T, Soma R, Fukagawa D, Tomabechi H, Takatori E, Nagasawa T, Sato S, Kagabu M, et al. A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease. Healthcare. 2019; 7(3):109. https://doi.org/10.3390/healthcare7030109

Shoji, Tadahiro, Hisashi Eto, Takanori Sato, Rikako Soma, Daisuke Fukagawa, Hidetoshi Tomabechi, Eriko Takatori, Takayuki Nagasawa, Seiya Sato, Masahiro Kagabu, and et al. 2019. "A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease" Healthcare 7, no. 3: 109. https://doi.org/10.3390/healthcare7030109

Shoji, T., Eto, H., Sato, T., Soma, R., Fukagawa, D., Tomabechi, H., Takatori, E., Nagasawa, T., Sato, S., Kagabu, M., & Baba, T. (2019). A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease. Healthcare, 7(3), 109. https://doi.org/10.3390/healthcare7030109